NCT05748834View on ClinicalTrials.gov

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 24, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Breast Cancer
Interventions
DRUG

Tucatinib

Participants will receive tucatinib 300mg by mouth twice daily continuously (days 1-28) of each 28 day cycle.

DRUG

Doxil

Participants will receive Doxil 40mg/m2 intravenously on day 1 of each 28 day cycle (with a maximum cumulative dose of 550mg/m2).

Trial Locations (8)

19020

RECRUITING

Alliance Cancer Specialists, Bensalem

21044

RECRUITING

Maryland Oncology Hematology, Columbia

23502

RECRUITING

Virginia Oncology Associates, Norfolk

24153

RECRUITING

Blue Ridge Cancer Care (Oncology & Hematology Assoc of SW Virginia, Inc), Salem

37203

RECRUITING

SCRI Oncology Partners, Nashville

ACTIVE_NOT_RECRUITING

Tennessee Oncology, Nashville

75246

RECRUITING

Texas Oncology- DFW, Dallas

78240

RECRUITING

Texas Oncology- San Antonio, San Antonio

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT05748834 - Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter